BioNTech (BNTX) news

Biontech SE: Canaccord Genuity cuts target price to $132 from $136

BioNTech SE has seen its target price cut by Canaccord Genuity, with analysts reducing their estimate to $132 from a previous $136. The adjustment reflects ongoing evaluations of the company’s financial and operational performance, including factors such as valuation, earnings revisions, and…

BioNTech (BNTX) shares fell 5.25% in premarket trading after the company reported a Q2 2026 earnings miss and lowered full-year guidance.

BioNTech SE (BNTX) shares declined 5.25% in premarket trading on October 13, 2026, following the company’s Q2 2026 earnings report, which fell short of expectations and prompted a downward revision of its full-year guidance. The biotechnology firm cited challenges in scaling production for new…

Biontech drops 5.6% as BNT113 misses primary endpoint in trial

Biontech's BNT113 misses PFS endpoint in head/neck cancer trial

BioNTech SE (Nasdaq: BNTX) announced that its mRNA cancer immunotherapy candidate, BNT113, did not meet the primary endpoint of progression-free survival (PFS) in a clinical trial for head and neck squamous cell carcinoma (HNSCC). The trial, part of the AHEAD-MERIT study (NCT04534205), evaluated…

Biontech SE - Trial will continue to evaluate second dual primary endpoint of overall survival

BioNTech SE (NASDAQ: BNTX) has announced that its ongoing Phase 2 clinical trial will continue to evaluate the second dual primary endpoint of overall survival (OS) for the investigational therapy. The trial is assessing the safety and efficacy of the treatment in a specific patient population,…